A research-framed overview of retatrutide dosage: the titration schedules and doses used in clinical trials, its ~6-day half-life, and reconstitution math. Research-use-only, not medical advice.
Retatrutide is an investigational triple receptor agonist — it activates the GIP, GLP-1, and glucagon receptors on a single acylated peptide backbone. Most of the public interest in "retatrutide dosage" traces back to a handful of clinical trials, where dose and titration schedule were controlled variables rather than lifestyle choices. This page collects what the published literature actually reports about retatrutide dosing: the escalation schedules used in trials, the pharmacokinetic context that explains weekly administration, and the reconstitution arithmetic that turns a lyophilized vial into a measured concentration.
Retatrutide carries a fatty diacid side chain that binds circulating albumin. That albumin binding shields the peptide from rapid renal clearance and enzymatic breakdown, extending its reported half-life to roughly 6 days. A half-life in that range is what makes a once-weekly subcutaneous cadence pharmacokinetically coherent: plasma concentrations rise and fall gently across the seven-day interval rather than spiking and crashing. Published pharmacokinetic summaries also note that steady-state plasma levels are reached after approximately four to five weekly doses, and that exposure is broadly dose-proportional across the studied range. This half-life framing is the single most important piece of dosing context — it is the reason trials titrated over weeks rather than days.
For a fuller mechanism-level treatment of how the triagonist works, see the retatrutide research overview.
The most-cited human data comes from the Phase 2 obesity trial (Jastreboff et al., New England Journal of Medicine, 2023), a 48-week randomized, double-blind, placebo-controlled study in adults with obesity or overweight with a weight-related comorbidity.
The recurring theme across the literature is gradual titration. Investigators used slow dose escalation specifically because it improved gastrointestinal tolerability — nausea and related effects cluster around dose increases — while still reaching high maintenance exposures. The published data support the general principle that stepping up slowly, over weeks, was better tolerated than jumping to a target dose.
Retatrutide ships as a lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water before any volume can be measured. The math is deterministic once you fix two numbers: the milligrams in the vial and the millilitres of diluent you add.
Worked example with a 10 mg vial:
Change the diluent volume and every number downstream changes. Reconstituting the same 10 mg vial with 2 mL halves the concentration to 5 mg/mL (50 mcg/unit), so the same 2 mg dose now measures 40 units — useful when smaller volumes are hard to draw accurately. The larger 20 mg and 30 mg vials follow the identical formula: concentration = total mg ÷ mL of water added.
If any of that arithmetic is unfamiliar, work through the dosing math guide and the reconstitution 101 guide before touching a vial. Getting the concentration wrong is the most common source of order-of-magnitude measurement error.
Retatrutide remains investigational. As of 2026 it has not completed the full Phase 3 program, and the long-term dosing, safety, and durability questions that Phase 3 trials exist to answer are still open. The dose–response relationship observed in Phase 2 was still climbing at the highest studied dose, which means the "optimal" maintenance dose is genuinely unsettled science, not a solved figure. Treat every number on this page as a snapshot of a moving research literature.
What doses of retatrutide were used in the clinical trials? The Phase 2 obesity trial studied maintenance doses of 1 mg, 4 mg, 8 mg, and 12 mg once weekly, with subjects titrated up from a low starting dose (2 mg or 4 mg) over several weeks.
Why is retatrutide titrated up slowly instead of started at the target dose? Published trials escalated the dose gradually because slower titration improved gastrointestinal tolerability — nausea and similar effects tend to concentrate around dose increases — while still allowing subjects to reach high maintenance exposures.
What is the half-life of retatrutide? Pharmacokinetic summaries report a half-life of approximately 6 days, which is the basis for its once-weekly subcutaneous dosing. Steady-state plasma levels are reached after roughly four to five weekly doses.
How do you calculate a dose from a reconstituted vial? Concentration equals the total milligrams in the vial divided by the millilitres of bacteriostatic water added. For a 10 mg vial reconstituted with 1 mL, that is 10 mg/mL, or 100 mcg per unit on a U-100 syringe. See the dosing math and reconstitution guides for the full method.
Is any of this a recommended dose? No. These are research figures from the published literature, provided for educational context only. This material is research-use-only and is not medical advice or a dosing recommendation for any person.
